Much like fictional superheroes who are dedicated to protecting the vulnerable with their supernatural abilities, a newly discovered class of ‘Hero’ proteins with unusual properties can prevent toxic protein aggregation seen in several neurodegenerative disorders, such as MND. This finding may have potential for new treatments and applications in biotechnology.
This blog is part of the ‘Highlights from Perth’ collection of articles, where you can read about the content of some of the talks and posters presented at the 30th International Symposium on ALS/MND in Perth. Presentations have a code beginning with ‘C’ followed by a number (e.g. C50) to help locate the specific abstract in the official abstract book.
People with MND may experience difficulties with chewing and swallowing (dysphagia), problems with hand and arm control, reduced mobility and fatigue, which can make the effort of eating and drinking tiring. Dysphagia can affect around 85% of people with MND at some point throughout their disease progression. This is due to a weakening of the muscles in the mouth and throat, making it harder to eat and drink. Some people with MND choose to have a gastrostomy – a surgical opening through the abdomen into the stomach. This allows tube feeding – a way of passing specially prepared food and fluids straight into the stomach. Adapting nutritional intake and monitoring weight is important to help avoid unintentional weight loss that is associated with faster disease progression and shorter survival.
We’ve stepped into the New Year! As part of the 30th International Symposium, the first ever Global Walk to D’Feet MND took place to raise awareness of ALS/MND. People affected by MND, scientists, and delegates from around the world made their way along the 5 km course which followed the route of Perth’s picturesque Swan River.Read More »
On top of all the sharing of research and networking, the International Symposium is a time to celebrate the huge achievements of individuals/teams that contribute to the ALS/MND community. There are too many outstanding and dedicated individuals to mention but some are recognised through several awards. Here we present the awards and the winners of the 30th International Symposium – warmest congratulations to all for their successes.Read More »
This blog is part of the ‘Highlights from Perth’ collection of articles, where you can read about the content of some of the talks and posters presented at the 30th International Symposium on ALS/MND. All presentations have a code beginning with ‘C’ followed by a number (e.g. C50). This will help you locate the specific abstract mentioned throughout the post in the official abstract book.
Researchers are invited to present their work as either a platform (oral) presentation or as a poster. Session 2B of the Symposium’s platform presentations looked at clinical trials. Here we summarise the session with four talks reporting concepts, updates and results of the trials being investigated. This includes the Healey ALS Platform Trial, Ibudilast, NurOwn, and Tofersen.
Hi all! I’m Riddhi and I’ve just joined the MND Association as a ‘Research Information Co-ordinator’ in the Research Development Team 😊
You’ll probably see me across the blog, from writing posts on exciting updates in MND research to replying to your comments, so I thought it would be nice to introduce myself and my background (including how I used ladybirds in neurodegenerative diseases). I’m thrilled to be part of the organisation that continuously strives towards helping people living with and affected by MND through funding research, campaigning and providing care and support. I look forward to exploring all the studies that contribute to finding an effective treatment or cure and then communicating these to you.Read More »